The company submitted an application for a seasonal flu vaccine it believes to be a key growth driver in the years ahead.

Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an ...

The mRNA-based vaccines that turned the tide of the COVID-19 pandemic currently account for almost all the value of the mRNA vaccine/therapeutic market. Indeed, the vaccine-led response to the ...

SEOUL, South Korea--(BUSINESS WIRE)--Lemonex Inc., a biotechnology company developing innovative messenger RNA (mRNA) and siRNA therapeutics based on a novel nanoparticle drug delivery system ...

Innovation Center of NanoMedicine (Center Director: Prof. Kazunori Kataoka) has announced that Prof. Satoshi Uchida (Principal Research Scientist), who is also Associated Professor of the Kyoto ...

Ottawa, Dec. 11, 2025 (GLOBE NEWSWIRE) -- The global mRNA quality monitoring market size is calculated at USD 1.37 billion in 2025 and is expected to reach around USD 2.5 billion by 2034, growing at a ...

STONY BROOK, NY / ACCESSWIRE / August 23, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the filing with the ...

CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, has announced the launch of an advanced animal mRNA vaccine platform to accelerate the development ...

Moderna, Inc. (NASDAQ:MRNA) today announced that it had voluntarily withdrawn the pending Biologics License Application (BLA) seeking approval for its COVID-19 and Influenza combination vaccine for ...

(MENAFN- GlobeNewsWire - Nasdaq) The global mRNA quality monitoring market size was valued at USD 1.28 billion in 2024 and is predicted to hit around USD 2.5 billion by 2034, rising at a 6.97% CAGR, a ...